A significant fraction of both early-stage and locally advanced lung cancer patients are treated with radiotherapy. In recent years, stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy, has emerged as a promising treatment for early-stage, medically inoperable non-small-cell lung cancer (NSCLC) and oligometastatic lung tumors. 1, 2 Local recurrence in these patients is uncommon and is usually reported to be less than 10%. 3, 4 In contrast, patients with locally advanced NSCLC are often treated with conventionally fractionated radiation therapy (CFRT), which is associated local recurrence rates of approximately 50%. 5 In addition, patients with NSCLC are prone to developing second malignancies, which may arise within or near previously irradiated areas. The optimal management of patients with recurrent or new tumors in previously irradiated regions remains a challenging therapeutic problem.
Options for the treatment of locally recurrent disease are limited, mainly consisting of chemotherapy, resection, or reirradiation. 6, 7 Reirradiation of locoregional failures with CFRT is controversial, given concerns regarding radioresistance of previously irradiated tumors and the risks of exceeding the radiation tolerances of adjacent normal tissue. Published reports of reirradiation of recurrent lung tumors using CFRT describe varying doses and target volumes and are primarily palliative in intent. 8 SABR represents an intriguing treatment approach for locally recurrent lung tumors. However, little is known about the efficacy and toxicity of such an approach. Here we report our institutional experience using SABR for the treatment of locally recurrent thoracic tumors.
MATERIALS AND METHODS
We conducted a retrospective review of all patients treated with lung tumor SABR at the Stanford Cancer Institute from January 2004 to June 2010, who had been previously treated with CFRT or SABR and who had biopsy-confirmed recurrent or second lung tumor occurring within the previous treatment field. We compared their outcomes with the outcomes of a cohort of previously unirradiated lung tumors treated with SABR during the same time period.
We have previously described our techniques for SABR. 9 We obtained follow-up diagnostic computed tomographic scan of the thorax and/or positron emission tomography (PET)-computed tomography (CT) at approximately 2 months post-SABR, then every 3 months for the first year, every 4 months for the second year, every 6 months for the third year, and yearly thereafter. Local failure (LF) was defined as recurrence We scored esophageal injury, radiation pneumonitis, and chest-wall toxicity. LC, progression-free survival (PFS), and overall survival (OS) were compared using the Kaplan-Meier method. Statistical significance was assessed using the log-rank test. Potential toxicity differences between the two treatment groups were assessed using the χ 2 test.
RESULTS
Patient, tumor, and treatment characteristics are shown in Table 1 . A total of 15 patients with 17 lung tumors met the criteria for this analysis. Median follow-up was 15 months (range, 4-65 months). The control group consisted of 111 patients with 135 lung tumors. Prescribed biologically effective dose (BED) at the PTV margin for the reirradiation cohort's initial treatment ranged from 60 to 112.5 Gy (median 87.5 Gy), and from 60 to 112.5 Gy for the SABR retreatment course (median 80 Gy). Median total BED (including the original course) was 157.6 and 87.5 Gy for the reirradiation cohort and control groups, respectively. Only one reirradiated tumor was retreated with a BED of more than 100 Gy. The median time from prior treatment in the reirradiation cohort was 16 months.
LC for all treated tumors is shown in Figure 1A . Twelvemonth actuarial LC was 65.5% for the reirradiated group and 92.1% for the control group (p < 0.001). There were a total of seven LFs in the reirradiation cohort and four of these were accompanied by regional or distant failure. Twelve-month actuarial PFS and OS did not differ significantly between the two groups and is shown in Figures 1B and C . Twelve-month actuarial PFS and OS for the reirradiated group were 58.2% and 80%, respectively. For the control group, 12-month actuarial PFS and OS were 71.1% and 92.9%, respectively.
We observed a significant difference in LC when the time interval from the initial treatment to the second treatment was less than or equal to the median of 16 months. As seen in Figure 1D , 12-month actuarial LC for tumors whose time interval between treatments was 16 months or less was 46.7%, compared with 87.5% for tumors in which the time interval between radiation treatments exceeded 16 months (p = 0.042). Although there were trends toward worse actuarial PFS and OS in tumors with short retreatment intervals compared with those with longer median intervals (12-month PFS 46.7% versus 70% p = 0.099) and OS (66.7% versus 100%, p = 0.286), these were not statistically significant.
Tumors that were reirradiated after an initial course of SABR are a particularly interesting subset of our reirradiation cohort given the high total doses they received (Fig. 2) . This group includes four patients, who received initial SABR regimens of 25 Gy in a single fraction (three patients) and 50 Gy in four fractions (one patient), and who were retreated with regimens of 20/1 (two patients), 45/4 (one patient), and 50/4 (one patient). Of these four patients, three remain controlled both locally and distantly after the second course of SABR. The remaining patient failed simultaneously in the regional lymph nodes and locally 7 months after retreatment.
Overall toxicity was extremely low, and no significant differences were seen between the reirradiated and control groups. Pneumonitis of grade 2 or higher was observed in none of the reirradiated patients and 13 (11.6%) of the control patients (p = 0.16). Chest-wall toxicity was observed in one (6.7%) of the reirradiated patients and 11 (10%) of the control patients (p = 0.69). Esophagitis was only observed in a single patient in the control group (0.9%). No grade 4 or higher toxicities were observed. Patients who were retreated with SABR after developing LF from a previous course of SABR also tolerated reirradation well, with only a single episode of grade-2 chest-wall toxicity occurring in this group. One patient with a central lesion near the aortic arch developed ipsilateral vocalcord paralysis, which was possibly secondary to recurrent laryngeal nerve toxicity.
DISCUSSION
The treatment of patients with isolated, locally relapsed lung cancer is a difficult clinical problem, especially in the setting of previous radiation treatment. SABR is an appealing treatment option, but little is known about its use in the setting of reirradiation. At our institution, we have been employing SABR for such patients, using relatively conservative doses to decrease the chance of normal tissue toxicity. In this study, we present our initial experience of using SABR for previously irradiated lung tumors.
Compared with a cohort of primary lung tumors treated during the same time period, reirradiated patients displayed significantly reduced LC. This is most likely attributable to the fact that we employed retreatment fractionation regimens with BEDs less than 100 Gy because of initial concerns about potential toxicity of reirradiation.
Although high-dose reirradiation raises concerns about potential side effects, we observed relatively low levels of toxicity, similar to those seen in SABR in previously unirradiated patients. Kelly et al. 10 recently reported a series of 36 patients who received SABR after thoracic CFRT, of which 11 were analogous to our reirradiation cohort because they developed recurrences in prior high-dose regions. The authors treated the majority of patients with 50 Gy in four fractions and noted excellent LC rates of 92%. However, high rates of toxicity were seen in this series, with 33% grade-3 toxicity and more than 50% of patients experiencing grade 2 or higher pneumonitis. This contrasts with our data, where lower levels of control were seen but with minimal toxicity. Another study by Seung et al. 11 included eight patients and used radiation doses of 40 to 60 Gy in three to five fractions with reported LC rates in the range of 80% to 90%. Taken together, our findings and the two previous reports suggest that SABR for reirradiation can be performed safely and that it is possible to achieve high rates of LC. However, prospective studies are clearly needed to identify the optimal dose for SABR of previously irradiated tumors.
Significantly, we found that longer intervals between the initial treatment and reirradiation were associated with better local control. We also observed a trend for worse OS and PFS in patients with shorter time to initial recurrence. A similar observation with regard to OS has been reported in relapsed NSCLC patients reirradiated using CFRT. 12 Notably, in the SABR reirradiation study by Seung et al. all but one of the eight patients had intervals of more than 15 months between the original course and SABR reirradiation. Their reported LC rate of 86% agrees with what we observed in patients who had had similarly long intertreatment intervals. These findings provide useful prognostic information and suggest that dose escalation even at the risk of higher toxicity may be warranted for tumors with shorter intervals between initial treatment and reirradiation.
We also report on the outcomes of four patients who were retreated with SABR for LF after a previous course of SABR. To the best of our knowledge, these are the first reported data for such patients. Given the widespread adoption of lung SABR, this clinical situation will arise more frequently in the future. Currently, management options that may be considered for patients developing LF after SABR include chemotherapy and surgical resection in medically operable candidates. 13, 14 Our data suggest that repeat SABR may also be considered, although this approach needs to be prospectively evaluated in a larger group of patients.
Limitations of our study include the retrospective nature of the analysis and its somewhat limited follow-up time. The study is also limited by heterogeneity in tumor type, because it includes both metastatic tumors and primary lung tumors. It should also be noted that our cohort did not include any recurrent tumors very close to the spinal cord or brachial plexus.
In conclusion, our findings demonstrate that SABR is a promising tool for the salvage treatment of recurrent tumors that were previously irradiated. Prospective studies establishing the optimal dose and fractionation schedule are needed. 
